Business
Spectral to Present at the 11th Annual Japanese Society of Critical Care and Endotoxemia on the use of EAA(TM) in Critically Ill Patients
Spectral to Present at the 11th Annual Japanese Society of Critical Care and Endotoxemia on the use of EAA(TM) in Critically Ill Patients.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\nTORONTO, Feb. 9 /CNW/ - Spectral today announces its participation in the\nJapanese Society of Critical and Endotoxemia Meeting, February 9 - 11, 2007,\nin Tokyo. Dr. Paul Walker, President and CEO of Spectral is the invited key\nnote speaker and will talk on the role of Endotoxin in several critical\nillnesses, as measured by the EAA(TM). Ms. Debra Foster, Director of\nSpectral's Sepsis Program will be presenting clinical experience on the use of\nEAA(TM).\n\n\n\"This is a very important meeting for Spectral and its Joint Alliance\nPartner Toray Medical, as there will be a number of lectures presented by\nJapanese Clinicians, where linking the use of the EAA(TM) in patients with\ntherapeutic interventions has led to significant benefit in patient care,\"\nstated Dr. Paul Walker.\n\n\n\"In addition, we are near completion of a multi-site combined efficacy\nstudy using the EAA(TM) and Toray's PMX column together,\" stated Ms. Foster.\n\"Toray's PMX column is an effective therapy for Endotoxemia and the EAA(TM) is\nable to identify patients who are Endotoxemic and thus might benefit from the\ntherapy, as well as guiding the use of this intervention, leading to better\npatient care.\"\n\n\nToray Medical Co., Ltd. is a subsidiary company of Toray, a leading\ndiversified chemicals corporate group that has been technology-focused since\nits foundation in 1926. The company's operations are underpinned by\ntechnological expertise in organic synthetic chemistry, polymer chemistry, and\nbiochemistry. These innovative technologies have yielded \"advanced materials\"\nthat Toray is now exploiting to provide customers with comprehensive solutions\nthrough Fibers and Textiles, Plastics and Chemicals, IT-related Products,\nCarbon Fiber Composite Materials, Environment and Engineering, Life Science\nand Other Business divisions. In FY2005, Toray had consolidated sales of \n1,427 billion yen (approx $12 billion US), and over 33,000 employees\nworldwide. For further information, please check www.toray.co.jp.\n\n\nSpectral is a developer of innovative technologies for comprehensive\ndisease management. Spectral provides accurate and timely information to\nclinicians enabling the early initiation of appropriate and targeted therapy.\nCurrent products include Spectral's FDA approved rapid West Nile Virus (WNV)\nassay and its FDA approved rap...